Phosphodiester content measured in human liver by in vivo 31P MR spectroscopy at 7 tesla

Phosphorus (31P) metabolites are emerging liver disease biomarkers. Of particular interest are phosphomonoester and phosphodiester (PDE) “peaks” that comprise multiple overlapping resonances in 31P spectra. This study investigates the effect of improved spectral resolution at 7 Tesla (T) on quantifying hepatic metabolites in cirrhosis.

[1]  Wolfgang Bogner,et al.  Phosphatidylcholine contributes to in vivo 31P MRS signal from the human liver , 2015, European Radiology.

[2]  F. Chan,et al.  Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. , 2014, Journal of hepatology.

[3]  Jimmy D Bell,et al.  Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models. , 1996, Gut.

[4]  A. Qayyum,et al.  MR spectroscopy of the liver: principles and clinical applications. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.

[5]  J. Bruzzi,et al.  Liver biopsy. , 2001, The New England journal of medicine.

[6]  Paul A. Bottomley,et al.  NMR Spectroscopy of the Human Heart , 2009 .

[7]  M. Stepanova,et al.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  T. Scheenen,et al.  Repeatability of 31P MRSI in the human brain at 7 T with and without the nuclear Overhauser effect , 2016, NMR in biomedicine.

[9]  Wolfgang Bogner,et al.  One‐dimensional image‐selected in vivo spectroscopy localized phosphorus saturation transfer at 7T , 2014, Magnetic resonance in medicine.

[10]  K Püschel,et al.  Standard liver volume in the Caucasian population. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  B. L. Welch.  The generalisation of student's problems when several different population variances are involved. , 1947, Biometrika.

[12]  J. van der Grond,et al.  31P magnetic resonance spectroscopy of the liver: Correlation with standardized serum, clinical, and histological changes in diffuse liver disease , 1995, Hepatology.

[13]  D. Gadian,et al.  Phosphodiesters in the Liver: The Effect of Field Strength on the 31P Signal , 1989, Magnetic resonance in medicine.

[14]  Wolfgang Bogner,et al.  In vivo 31P magnetic resonance spectroscopy of the human liver at 7 T: an initial experience , 2014, NMR in biomedicine.

[15]  T. Brown,et al.  Molar Quantitation of Hepatic Metabolites In Vivo in Proton‐decoupled, Nuclear Overhauser Effect Enhanced 31P NMR Spectra Localized by Three‐dimensional Chemical Shift Imaging , 1996, NMR in biomedicine.

[16]  B. Maharaj,et al.  SAMPLING VARIABILITY AND ITS INFLUENCE ON THE DIAGNOSTIC YIELD OF PERCUTANEOUS NEEDLE BIOPSY OF THE LIVER , 1986, The Lancet.

[17]  M. Oudkerk,et al.  Understanding the discrepancies between 31P MR spectroscopy assessed liver metabolite concentrations from different institutions. , 1998, Magnetic resonance imaging.

[18]  Jimmy D Bell,et al.  Improved preservation solutions for organ storage: a dynamic study of hepatic metabolism. , 1999, Transplantation.

[19]  Antonin Skoch,et al.  Etiology and functional status of liver cirrhosis by 31P MR spectroscopy. , 2005, World journal of gastroenterology.

[20]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .

[21]  M. Robson,et al.  Reproducibility of 31P cardiac magnetic resonance spectroscopy at 3 T , 2009, NMR in biomedicine.

[22]  K. Wolf,et al.  Einfluß der Ernährungslage auf das 31P-MR-Spektrum der gesunden Leber , 1990 .

[23]  M. Blachier,et al.  Report Title: The burden of liver disease in Europe: a review of available epidemiological data , 2013 .

[24]  P. Giral,et al.  Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.

[25]  Serge Akoka,et al.  A new method for absolute quantitation MRS metabolites , 1997, Magnetic resonance in medicine.

[26]  Roland Kreis,et al.  The trouble with quality filtering based on relative Cramér‐Rao lower bounds , 2016, Magnetic resonance in medicine.

[27]  Ewald Moser,et al.  Abnormal hepatic energy homeostasis in type 2 diabetes , 2009, Hepatology.

[28]  M. Robson,et al.  Receive array magnetic resonance spectroscopy: Whitened singular value decomposition (WSVD) gives optimal Bayesian solution , 2010, Magnetic resonance in medicine.

[29]  P. Lundberg,et al.  Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. , 2008, European journal of radiology.

[30]  W. Lau,et al.  Biliary drainage for obstructive jaundice enhances hepatic energy status in humans: a 31-phosphorus magnetic resonance spectroscopy study , 2002, Gut.

[31]  D van Ormondt,et al.  Cramér–Rao bounds: an evaluation tool for quantitation , 2001, NMR in biomedicine.

[32]  C. Muhle,et al.  Influence of different fasting periods on P-31-MR-spectroscopy of the liver in normals and patients with liver metastases , 2004, European Radiology.

[33]  J. Bunke,et al.  Quantitative liver 31P magnetic resonance spectroscopy at 3T on a clinical scanner , 2014, Magnetic resonance in medicine.

[34]  Stefan Neubauer,et al.  Ultrashort TE chemical shift imaging (UTE‐CSI) , 2005, Magnetic resonance in medicine.

[35]  S. Williams,et al.  Endoplasmic reticulum: the major contributor to the PDE peak in hepatic 31P-NMR spectra at low magnetic field strengths. , 1992, Biochimica et biophysica acta.

[36]  N. Lundbom,et al.  Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling. , 2010, Radiology.

[37]  Jimmy D Bell,et al.  A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver. , 1993, Biochimica et biophysica acta.

[38]  J. Hajnal,et al.  A comparison of single‐voxel clinical in vivo hepatic 31P MR spectra acquired at 1.5 and 3.0 Tesla in health and diseased states , 2011, NMR in biomedicine.

[39]  Cecilia Possanzini,et al.  31P MRSI and 1H MRS at 7 T: initial results in human breast cancer , 2011, NMR in biomedicine.

[40]  M. Roden,et al.  Characterization of the peak at 2.06 ppm in 31P magnetic resonance spectroscopy of human liver: phosphoenolpyruvate or phosphatidylcholine? , 2015, NMR in biomedicine.

[41]  Matthew D. Robson,et al.  Coil combination for receive array spectroscopy: Are data‐driven methods superior to methods using computed field maps? , 2015, Magnetic resonance in medicine.

[42]  Thomas H. Mareci,et al.  Essential considerations for spectral localization using indirect gradient encoding of spatial information , 1991 .

[43]  M. Trauner,et al.  Application of localized 31P MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease , 2014, European Radiology.

[44]  H. Blaszyk,et al.  Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C , 2006, Journal of Clinical Pathology.

[45]  L DelaBarre,et al.  BISTRO: An outer‐volume suppression method that tolerates RF field inhomogeneity , 2001, Magnetic resonance in medicine.

[46]  Stefan Neubauer,et al.  Human cardiac 31P magnetic resonance spectroscopy at 7 tesla , 2013, Magnetic resonance in medicine.

[47]  E. Moser,et al.  Three‐dimensional high‐resolution magnetic resonance spectroscopic imaging for absolute quantification of 31P metabolites in human liver , 2008, Magnetic resonance in medicine.

[48]  Welch Bl.  THE GENERALIZATION OF ‘STUDENT'S’ PROBLEM WHEN SEVERAL DIFFERENT POPULATION VARLANCES ARE INVOLVED , 1947 .

[49]  P. Roemer,et al.  The NMR phased array , 1990, Magnetic resonance in medicine.

[50]  E Moser,et al.  Quantitative ATP synthesis in human liver measured by localized 31P spectroscopy using the magnetization transfer experiment , 2008, NMR in biomedicine.

[51]  R. Buchli,et al.  Assessment of absolute metabolite concentrations in human tissue by 31P MRS in vivo. Part II: Muscle, liver, kidney , 1994, Magnetic resonance in medicine.

[52]  K. Sahlin,et al.  Adenine nucleotide content of human liver. Normal values and fructose-induced depletion. , 1975, Scandinavian journal of clinical and laboratory investigation.

[53]  J. Ruíz-Cabello,et al.  Phospholipid metabolites as indicators of cancer cell function , 1992, NMR in biomedicine.

[54]  E. Mezey,et al.  Sampling variability on percutaneous liver biopsy. , 1979, Archives of internal medicine.

[55]  R Pohmann,et al.  Accurate phosphorus metabolite images of the human heart by 3D acquisition‐weighted CSI , 2001, Magnetic resonance in medicine.

[56]  D. Menon,et al.  Effect of functional grade and etiology on in vivo hepatic phosphorus‐31 magnetic resonance spectroscopy in cirrhosis: Biochemical basis of spectral appearances , 1995, Hepatology.

[57]  P. Baunsgaard,et al.  THE VARIATION OF PATHOLOGICAL CHANGES IN THE LIVER EVALUATED BY DOUBLE BIOPSIES , 1979, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[58]  S Trattnig,et al.  Assessment of 31P relaxation times in the human calf muscle: A comparison between 3 T and 7 T in vivo , 2009, Magnetic resonance in medicine.

[59]  Jimmy D Bell,et al.  In vivo and in vitro hepatic phosphorus-31 magnetic resonance spectroscopy and electron microscopy in chronic ductopenic rejection of human liver allografts , 1998, Gut.

[60]  D. Small,et al.  Ternary and Quaternary Aqueous Systems Containing Bile Salt, Lecithin, and Cholesterol , 1966, Nature.

[61]  H. Kimura,et al.  Feasibility of liver weight estimation by postmortem computed tomography images: An autopsy study , 2014, Pathology international.

[62]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.